Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Johanna M Mattsson"'
Autor:
Johanna M Mattsson, Suvi Ravela, Can Hekim, Magnus Jonsson, Johan Malm, Ale Närvänen, Ulf-Håkan Stenman, Hannu Koistinen
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107819 (2014)
Prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3) exerts chymotrypsin-like proteolytic activity. The main biological function of PSA is the liquefaction of the clot formed after ejaculation by cleavage of semenogelins I and II i
Externí odkaz:
https://doaj.org/article/1f1c120f20594723b2832bec8b0fcda8
Autor:
Hannu Koistinen, Johanna M. Mattsson, Ulf-Håkan Stenman, Henna Ylikangas, Maija Lahtela-Kakkonen, Antti Poso
Publikováno v:
ChemMedChem. 11(18)
Kallikrein-related peptidase 3 (KLK3) is a prostatic serine protease shown to possess antiangiogenic properties which are exerted via its proteolytic activity. The antiangiogenic effect indicates that KLK3 may slow down the growth of prostate cancer;
Publikováno v:
The Prostate. 72:1588-1594
BACKGROUND Proteolytically active prostate-specific antigen (PSA or kallikrein-related peptidase 3, KLK3) has been shown to exert antiangiogenic properties. High levels of PSA in prostatic tumors may thus slow down cancer progression by inhibiting an
Autor:
Gerd Wohlfahrt, Ping Wu, Hannu Koistinen, Juhani Lahdenperä, Johanna M. Mattsson, Ulf-Håkan Stenman
Publikováno v:
The Prostate. 68:1143-1151
Background Prostate-specific antigen (PSA or KLK3) has been shown to inhibit angiogenesis, but it might also have tumor promoting activities. Thus, it may be possible to modulate prostate cancer growth by stimulating or inhibiting the activity of PSA
Autor:
Miikka Pakkala, Hannu Koistinen, Can Hekim, Lei Zhu, Ale Närvänen, Ulf-Håkan Stenman, Johanna M. Mattsson, Pirjo Laakkonen
Publikováno v:
bchm. 389:633-642
The prostate produces several proteases, the most abundant ones being kallikrein-related peptidase 3 (KLK3, PSA) and KLK2 (hK2), which are potential targets for tumor imaging and treatment. KLK3 expression is lower in malignant than in normal prostat
Autor:
Johan Malm, Can Hekim, Magnus P. Jonsson, Johanna M. Mattsson, Hannu Koistinen, Suvi Ravela, Ulf-Håkan Stenman, Ale Närvänen
Publikováno v:
PLoS ONE
PLoS ONE; 9(9), no e107819 (2014)
PLoS ONE, Vol 9, Iss 9, p e107819 (2014)
PLoS ONE; 9(9), no e107819 (2014)
PLoS ONE, Vol 9, Iss 9, p e107819 (2014)
Prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3) exerts chymotrypsin-like proteolytic activity. The main biological function of PSA is the liquefaction of the clot formed after ejaculation by cleavage of semenogelins I and II i
Publikováno v:
The Prostate. 72(14)
Proteolytically active prostate-specific antigen (PSA or kallikrein-related peptidase 3, KLK3) has been shown to exert antiangiogenic properties. High levels of PSA in prostatic tumors may thus slow down cancer progression by inhibiting angiogenesis.
Autor:
Sanni Matero, Maija Lahtela-Kakkonen, Antti Poso, Björn Windshügel, Johanna M. Mattsson, Hannu Koistinen, Juha A. E. Määttä, Ulf-Håkan Stenman, Henna H. Härkönen
Publikováno v:
ChemMedChem. 6(12)
Kallikrein-related peptidase 3 (KLK3), also known as prostate-specific antigen (PSA), is the most useful biomarker for prostate cancer (PCa). KLK3 is suggested to play a role in regulating cancer growth through anti-angiogenic activity in vivo and in
Publikováno v:
Scandinavian journal of clinical and laboratory investigation. 69(4)
The prostate produces high levels of prostate-specific antigen (PSA, also known as kallikrein-related peptidase 3, KLK3), which is a potential target for tumor imaging and treatment. Although serum PSA levels are elevated in prostate cancer, PSA expr
Publikováno v:
The Prostate. 68(9)
BACKGROUND The prostate produces high levels of prostate-specific antigen (PSA), which has been shown to exert anti-angiogenic properties and thus might slow down prostate tumor growth. It has been suggested that the protease activity of PSA is not n